Health Policy and Management (보건행정학회지)

Korean Academy of Health Policy and Management (한국보건행정학회)
권호 표지
DOI QR코드

DOI QR Code

The Effect of Drug Vintage on Mortality : Economic Effect of New Drug

약의 허가시점분포가 사망률에 매치는 영향 : 신약의 거시경제적 효과

  • Published : 2006.12.30
Download PDF
⟨ Previous Next ⟩

Abstract

Technological innovation has been regarded as the core competence for the economic growth of individual, as well as organization and country. Pharmaceutical innovation, what we call new medicines, influence people's longevity and productivity by increasing output per hour worked. Therefore, using claims data on virtually all the drugs and diseases of over 550,000 people enrolled in National Health Insurance Program in Korea, we examined the impact of the vintage (original FDA and KFDA approval year) of drugs used to treat a patients from July 1st to December 31st in 2002 on the patient's mortality at the end of 2004, controlling for demographic characteristics(age and sex), utilization of medical services, and the nature and complexity of illness. We found that people using newer drugs are less likely to die at the end of 2004, conditional on covariates. The estimated mortality rates were declining with respect to drug vintage for 1970s, 1980s and 1990s and highly significant. In addition to estimating the model for the entire sample, we estimated the model separately for several disease categories classified by Korean Classification of Disease. Estimates of three drug vintage variables for subgroups of people with (1)neoplasms, (2)endocrine, nutritional and metabolic diseases, and (3)the diseases of circulatory system displayed similar patterns.

Keywords

References

  1. 과학기술부. 과학기술 연구 활동 조사보고. 2001
  2. 권명중, 유정식, 이태정, 양준모. 산업 수명주기론을 응용한 연구개발투자의 경제적 평가:의료기기산업을 중심으로. 중소기업연구. 제 27호 제2권. 2005
  3. 김종권. 제약 산업 R&D투자 효과분석. 보건경제연구. 2003; 9(1)47:-58
  4. 박용규. 통계시리즈 (IX): 로지스틱 회귀분석. 가정의학회지 제 22권 제 7호.2001
  5. 유승훈, 양창영. 공공보건지출과 경제적 성과에 대한 다국가 분석. 재정논집. 제 19집 제 1호. 2004
  6. 이공래. 지역기술혁신체제에서의 공공연구기관의 역할과 발전 방향. 과학기술정책연구원 정책자료. 2004
  7. 이태진, 김재용, 성주헌. 장애보정손실년수를 이용한 우리나라 주요 심혈관계 질환의 질병부담 추정. 보건경제연구. 2002; 8(1): 91-100
  8. 이훈영. 이훈영교수의 마케팅 조사론. 도서출판 청람. 2005
  9. 정광모, 최용석. 로지스틱 회귀와 응용-SAS 예제와 해석 중심. 자유 아카데미. 2003
  10. 정기택 외. 진료비 청구명세서 내용 및 작성. 청구방법 개선의 타당도 제고 방안 연구. 건강보험심사평가원. 경희대학교 의료산업연구원. 2003
  11. 정영호, 고숙자. 5 대 사망원인 질병의 사회. 경제적 비용추계. 재정논집. 2004; 18(2): 77-104
  12. 정영호. 보건산업의 연구개발(R&D)파급 분석. 보건경제연구. 2002; 8(1):107-134
  13. 한국보건산업진흥원. 보건산업 실태조사 및 산업연관 분석. 2003
  14. 한국보건산업진흥원. 보건산업 백서. 2004
  15. Bahk, Byong-Hyong and Micheal Gort. Decomposing learning by doing in new plants. Journal of Political Economy. 1993; 101: 561-583 https://doi.org/10.1086/261888
  16. Barbara HM, 이은현 등 옮김. 보건통계분석. 군자출판사. 2002
  17. Berger, ML, Murray, JF, Xu, J, Pauly, M. Alternative Valuations of work loss and productivity. American College of Occupational and Environmental Medicine. 2001;43:18-24 https://doi.org/10.1097/00043764-200101000-00005
  18. Berndt, Ernst, Margaret K. Kyle, and Davina Ling. The long shadow of patent expiration: Do Rx to OTC switches provide an afterlife? Scanner data and price indexes, ed. 2003
  19. Boston Consulting Group. The contribution of pharmaceutical companies: What's at stake for america, executive summary. Unpublished report, Boston Consulting Group Inc. 1993
  20. Culter, David, and Mark McClellan. Is technological change in medicine worth it? Health Affairs. 2001; 20(5): pp.11-29 https://doi.org/10.1377/hlthaff.20.5.11
  21. Fagerberg, J. A technology gap approach to why growth rates differ. Research Policy. 1987; 16
  22. Freeman, C. and Soete, L. The economics of industrial innovation. Cambridge: The MIT Press. 1997
  23. Griliches, Z and Lichtenberg F. 'R&D and productivity at the industry level: Is there still a relationship?,' in R&D, patent and productivity. Zvi Griliches, ed. Chicago: Univ. of Chicago Press. 1984
  24. Hulten, Charles R. Growth accounting when technical changes embodied in capital. The American Economic Review. 1992; Vol. 82, No. 4. pp. 964-980
  25. IMS Health: :MIADS, MAT, June 2004
  26. Jones, C I. R&D based models of economic growth. Journal of Political Economy. 1995;103(4): 759-786 https://doi.org/10.1086/262002
  27. Lichtenberg, F and Siegel. The impact of R&D investment on productivity: New evidence using linked R&D-LRD data. Economic Inquiry. 1991;29: 203-28 https://doi.org/10.1111/j.1465-7295.1991.tb01267.x
  28. Lichtenberg, F. Do (more and better) drugs keep people out of hospitals? the American Economic Review; 1996; 86(2):384-388
  29. Lichtenberg, F. Pharmaceutical innovation, mortality reduction and economic growth. NBER. 1998; working paper 6569
  30. Lichtenberg, F. The allocation of publicly-funded biomedical research. NBER. 1998; working paper no. 6601
  31. Lichtenberg, F. The benefits and costs of newer drugs: evidence from the 1996 medical expenditure panel survey. NBER. 2001. working paper no. 8147
  32. Lichtenberg, F. Sources of U.S. longevity increase, 1960-1997. NBER. 2002; working paper no. 8755
  33. Lichtenberg, F. The effect of changes on drug utilization on labor supply and per capita output. National Bureau of Economic Research. 2002; working paper No. 9139
  34. Lichtenberg, F. Pharmaceutical embodied technical progress, longevity and quality of life: Drug as 'Equipment for your health'. National Bureau of Economic Research working paper no. 9351. 2002
  35. Lichtenberg, F. The impact of new drug launches on longevity: evidence from longitudinal, disease-level data from 52 countries, 1982-2001. NBER 2003. working paper 9754
  36. Lichtenberg, F. R The expanding pharmaceutical arsenal in the war on cancer. NBER. 2004a. working paper 10328
  37. Lichtenberg, F. The effect of drug vintage on survival: micro evidence from Puerto Rico's Medicaid program. NBER. 2004b; working paper no. 10884
  38. Mosby's Drug Consult CD-ROM
  39. Murphy, Kevin, and Robert Topel. The economic value of medical research. The value of medical research, ed. Chicago: Univ. of Chicago Press. 2002
  40. New York Times. Cholesterol pill linked to lower hospital bills. 1995; 27 March: p. A11
  41. Sakellaris P and Dan W. The production-side approach to estimating embodied technological change. Electronic Working Papers. University of Maryland. Department of Economics. 2000
  42. Romer, Paul. Endogenous technological change. Journal of Political Economy. 1990;98:S71-S102 https://doi.org/10.1086/261725
  43. Solow, RM. A contribution to the theory of economic growth. Quarterly Journal of Economics. 1956; 70: 65-94 https://doi.org/10.2307/1884513
  44. Solow, RM. Technical progress, capital formation and economic growth. The American Economic Review. 1962; Vol. 52, No. 2: pp. 76-86
  45. FDA New Drug Approval Reports(http://www.dfa.gov/cder/rdmt/defaulth.tml)
  46. http://100.naver.com/100.php?id=83267
  47. http://ezdrug.kfda.go.kr
  48. http://www.phrma.org/publications/publications//2005-03-17.1145.pdf
  49. http://www.phrma.org/publications/publications//2005-03-17.1145.pdf
  50. KMLE(http://drug.kmle.co.kr)
  51. National Science Foundation (http://www.nsf.gov/statistics/infbrief/nsf03306/)
  52. National Science Foundation (http://www.nsf.gov/statistics/infbrief/nsf03306/)
  53. 일간보사 의학신문 (http://www.bosa.co.kr/news_board/view.asp?news_pk=78029)
  54. 인구주요통계. 통계청 2005(http://kosis.nso.go.kr/cgi-bin/sws_999.cgi)
  55. 통계청(http://www.nso.go.kr/newnso/standard/disease/dis_search.html)
  56. 한국표준질병 . 사인분류 제 4차 개정판 (Korean Classification of Disease or KCD)

Cited by

  1. Life-expectancy gains from pharmaceutical drugs: a critical appraisal of the literature vol.9, pp.6, 2009, https://doi.org/10.1586/erp.09.64